RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives

PURPOSE: The effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with COVID-19 and diabetes mellitus (DM) remains unknown. We assessed the risk of death in COVID-19 inpatients based on the presence or absence of DM, arterial hypertension (AH) and the use of RAAS inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalangot, Mykola, Sheichenko, Nadiia, Gurianov, Vitaly, Zakharchenko, Tamara, Kravchenko, Victor, Tronko, Mykola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900734/
https://www.ncbi.nlm.nih.gov/pubmed/36755914
http://dx.doi.org/10.3389/fendo.2023.1077959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900734/
https://www.ncbi.nlm.nih.gov/pubmed/36755914
http://dx.doi.org/10.3389/fendo.2023.1077959

Ejemplares similares